153 related articles for article (PubMed ID: 28025866)
1. Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications.
Šefer D; Bižić-Radulović S; Kraguljac-Kurtović N; Bogdanović A; Čokić V; Miljić P; Beleslin-Čokić B; Knežević V; Mitrović-Ajtić O; Leković D; Gotić M
Int J Lab Hematol; 2017 Feb; 39(1):21-31. PubMed ID: 28025866
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
3. Update from the latest WHO classification of MPNs: a user's manual.
Passamonti F; Maffioli M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):534-542. PubMed ID: 27913526
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.
Lekovic D; Gotic M; Skoda R; Beleslin-Cokic B; Milic N; Mitrovic-Ajtic O; Nienhold R; Sefer D; Suboticki T; Buac M; Markovic D; Diklic M; Cokic VP
Ann Hematol; 2017 Mar; 96(3):393-404. PubMed ID: 27924369
[TBL] [Abstract][Full Text] [Related]
5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
6. Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.
Zheng CF; Zhao XX; Chen XH; Liu Z; Wang WJ; Luo M; Ren Y; Wang HW
Int J Lab Hematol; 2021 Aug; 43(4):645-650. PubMed ID: 33973741
[TBL] [Abstract][Full Text] [Related]
7. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Wang J; Ishii T; Zhang W; Sozer S; Dai Y; Mascarenhas J; Najfeld V; Zhao ZJ; Hoffman R; Wisch N; Xu M
Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
[TBL] [Abstract][Full Text] [Related]
8. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
9. Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes.
Hauck G; Jonigk D; Göhring G; Kreipe H; Hussein K
Cancer Genet; 2013 Apr; 206(4):116-23. PubMed ID: 23571153
[TBL] [Abstract][Full Text] [Related]
10. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2012 Jan; 53(1):123-9. PubMed ID: 21806350
[TBL] [Abstract][Full Text] [Related]
11. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
12. Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms.
Chen P; Wu B; Ji L; Zhan Y; Li F; Cheng L; Cao J; Chen H; Ke Y; Min Z; Sun L; Hua F; Chen H; Cheng Y
Front Med (Lausanne); 2021; 8():598182. PubMed ID: 34249954
[No Abstract] [Full Text] [Related]
13. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
14. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
Balduini A; Badalucco S; Pugliano MT; Baev D; De Silvestri A; Cattaneo M; Rosti V; Barosi G
PLoS One; 2011; 6(6):e21015. PubMed ID: 21698292
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
[TBL] [Abstract][Full Text] [Related]
16. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
[TBL] [Abstract][Full Text] [Related]
17. β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study.
Subotički T; Mitrović Ajtić O; Mićić M; Kravić Stevović T; Đikić D; Diklić M; Leković D; Gotić M; Čokić VP
Ultrastruct Pathol; 2018; 42(6):498-507. PubMed ID: 30582392
[TBL] [Abstract][Full Text] [Related]
18. A lasso and random forest model using flow cytometry data identifies primary myelofibrosis.
Zhang F; Wang YZ; Chang Y; Yuan XY; Shi WH; Shi HX; Shen JZ; Liu YR
Cytometry B Clin Cytom; 2024 Apr; ():. PubMed ID: 38647185
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
[TBL] [Abstract][Full Text] [Related]
20. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.
Molitor DCA; Boor P; Buness A; Schneider RK; Teichmann LL; Körber RM; Horvath GL; Koschmieder S; Gütgemann I
Ann Hematol; 2021 Jan; 100(1):97-104. PubMed ID: 33104881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
